CHROMATOGRAPHIC INSIGHTS: UPLC-TUV ANALYSIS OF GLUCOSAMINE AND CHONDROITIN IN DIETARY PRODUCTS
Abstract
Osteoarthritis (OA) is a prevalent chronic disease characterized by irreversible joint tissue damage, impacting cartilage, synovial membrane, and subchondral bone. This study explores the therapeutic potential of two compounds, glucosamine and chondroitin sulfate, in managing OA symptoms. Glucosamine, a vital component of chitin and mucopolysaccharides, is known for its role in connective tissue and cartilage formation. The safety profile of glucosamine, as demonstrated by research from the U.S. National Institutes of Health (NIH) and other sources, highlights its advantages over non-steroidal anti-inflammatory drugs (NSAIDs), with significantly fewer side effects observed. Furthermore, glucosamine does not interfere with glucose metabolism. Chondroitin sulfate, a sulfated glycosaminoglycan, is widely used in OA patient management. Its multifaceted effects on chondrocyte survival, modulation of cartilage matrix balance, and reduction of proinflammatory factors underscore its potential benefits. In subchondral bone osteoblasts, chondroitin sulfate contributes to enhanced OPG/RANKL ratio, indicative of improved bone health. This review consolidates evidence on the efficacy and safety of glucosamine and chondroitin sulfate in OA management, shedding light on their roles in mitigating joint degeneration and inflammation. These compounds offer promising avenues for OA treatment, warranting further research and clinical exploration.
